BioArctic AB’s partner Eisai published a presentation including a simulation of potential future sales for Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer’s disease.
BioArctic AB’s partner Eisai published a presentation including a simulation of potential future sales for Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer’s disease.